(68 days)
Not Found
Not Found
No
The summary describes a laboratory immunoassay for detecting antibodies, which is a standard biochemical test and does not mention any AI or ML components.
No
The device aids in diagnosis by detecting an autoantibody, but it does not treat or cure a disease or condition.
Yes
The device is described as "for use as an aid diagnosis of certain autoimmune disease". This directly indicates its diagnostic purpose.
No
The provided text describes an immunoassay, which is a laboratory test involving biological reagents and physical processes, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
The intended use clearly states that it is a "semiquantitative enzyme linked immunoassay for detecting IgA A class autoantibody to f2 glycoprotein I (B2 GPI) for use as an aid diagnosis of certain autoimmune disease thrombotic in the disorders...".
This description aligns with the definition of an IVD, which is a medical device used to examine specimens derived from the human body to provide information for diagnostic purposes. The device is performing a test on a biological sample (presumably blood or serum, although not explicitly stated) to detect a specific antibody (IgA anti-B2 GPI) as an aid in diagnosing certain conditions.
N/A
Intended Use / Indications for Use
semiquantitative enzyme linked immunoassay for detecting IgA A class autoantibody to f2 glycoprotein I (B2 GPI) for use as an aid diagnosis of certain autoimmune disease thrombotic in the disorders, such as those secondary to systemic lupus erythematosus (SLE) or other lupus-like disorders.
Product codes
MSV
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.5660 Multiple autoantibodies immunological test system.
(a)
Identification. A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/2 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus symbol.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT 20 1997
Mr. Brys Myers Requlatory Affairs INOVA Diagnostics, Inc. 10451 Roselle Street San Diego, California 92121
Re : K973006 QUANTA Lite™ B2 GPI IgA ELISA Trade Name: Regulatory Class: II Product Code: MSV Dated: Auqust 11, 1997 Received: August 13, 1997
Dear Mr. Myers:
We have reviewed your Section 510(k) notification of intent to market · the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the You provisions of the Federal Food, Druq, and Cosmetic Act (Act). may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Requlations.
1
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Page of
510(k) Number (if known): k 97 300 k QUANTA Lite™ B,GPI IgA Device Name:
Indications For Use:
semiquantitative enzyme linked immunoassay for detecting IgA A class autoantibody to f2 glycoprotein I (B2 GPI) for use as an aid diagnosis of certain autoimmune disease thrombotic in the disorders, such as those secondary to systemic lupus erythematosus (SLE) or other lupus-like disorders.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Teta E. Mason
(Division Sign-Off) Division of Clinical Laboratory Device 510(k) Number
Image /page/2/Picture/8 description: The image shows the words "Prescription Use" with an underline and a check mark above the underline. Below that, the text "(Pcx 21 CFR 801.109)" is shown. The text is in bold font. The image appears to be a label or a part of a document.
OR
Over-The-Counter Use
(Optional Format 1-2-96)